Loading the section…

RXST: financial statements from SEC — TradeAlmanac

RXST

RxSight, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	31/12/2025	31/12/2024
Revenue	134M	140M
Cost of revenue	31M	41M
Gross profit	103M	99M
Research and development	39M	34M
Selling, general and administrative	113M	101M
Operating expenses	151M	136M
Operating income	−48M	−37M
Interest expense	19,000	21,000
Pre-tax income	−39M	−27M
Income tax	66,000	50,000
Net income	−39M	−27M
Earnings per share	−0.95	−0.71
Earnings per share, diluted	−0.95	−0.71
Weighted average shares	41M	39M
Weighted average shares, diluted	41M	39M

Balance sheet

Metric	31/03/2026	31/12/2025	30/09/2025	30/06/2025	31/03/2025	31/12/2024	30/09/2024	30/06/2024
Cash and equivalents	18M	20M	30M	40M	28M	17M	17M	25M
Short-term investments	200M	208M	198M

Cash flow

Metric	31/12/2025	31/12/2024
Operating cash flow	−16M	−17M
Depreciation and amortisation	3M	4M
Share-based compensation	32M	25M
Capital expenditure	4M	5M
Investing cash flow	17M	−99M
Financing cash flow	2M

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator